Charles Schwab’s Ultragenyx Pharmaceutical RARE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $25.4M | Buy |
760,039
+201,553
| +36% | +$5.01M | ﹤0.01% | 1691 |
|
|
2026
Q1 | $11.7M | Sell |
558,486
-40,438
| -7% | -$911K | ﹤0.01% | 2028 |
|
|
2025
Q4 | $13.8M | Sell |
598,924
-1,236
| -0.2% | -$40.6K | ﹤0.01% | 1966 |
|
|
2025
Q3 | $18.1M | Sell |
600,160
-15,809
| -3% | -$474K | ﹤0.01% | 1790 |
|
|
2025
Q2 | $22.4M | Buy |
615,969
+22,848
| +4% | +$824K | ﹤0.01% | 1609 |
|
|
2025
Q1 | $21.5M | Sell |
593,121
-20,512
| -3% | -$853K | ﹤0.01% | 1604 |
|
|
2024
Q4 | $25.8M | Buy |
613,633
+19,112
| +3% | +$948K | ﹤0.01% | 1559 |
|
|
2024
Q3 | $33M | Buy |
594,521
+56,905
| +11% | +$2.9M | 0.01% | 1391 |
|
|
2024
Q2 | $22.1M | Buy |
537,616
+53,235
| +11% | +$2.27M | ﹤0.01% | 1609 |
|
|
2024
Q1 | $22.6M | Buy |
484,381
+12,556
| +3% | +$592K | 0.01% | 1537 |
|
|
2023
Q4 | $22.6M | Buy |
471,825
+75,100
| +19% | +$2.91M | 0.01% | 1524 |
|
|
2023
Q3 | $14.1M | Buy |
396,725
+19,487
| +5% | +$772K | ﹤0.01% | 1719 |
|
|
2023
Q2 | $17.4M | Buy |
377,238
+6,276
| +2% | +$291K | 0.01% | 1592 |
|
|
2023
Q1 | $14.9M | Sell |
370,962
-1,312
| -0.4% | -$56.3K | ﹤0.01% | 1671 |
|
|
2022
Q4 | $17.2M | Buy |
372,274
+7,168
| +2% | +$282K | 0.01% | 1544 |
|
|
2022
Q3 | $15.1M | Sell |
365,106
-186,020
| -34% | -$9.56M | 0.01% | 1584 |
|
|
2022
Q2 | $32.9M | Buy |
551,126
+10,382
| +2% | +$639K | 0.01% | 1037 |
|
|
2022
Q1 | $39.3M | Buy |
540,744
+14,561
| +3% | +$1.01M | 0.01% | 1044 |
|
|
2021
Q4 | $44.2M | Buy |
526,183
+12,334
| +2% | +$1M | 0.01% | 980 |
|
|
2021
Q3 | $46.3M | Buy |
513,849
+16,748
| +3% | +$1.51M | 0.02% | 929 |
|
|
2021
Q2 | $47.4M | Sell |
497,101
-102,330
| -17% | -$10.7M | 0.02% | 910 |
|
|
2021
Q1 | $68.3M | Buy |
599,431
+56,157
| +10% | +$7.65M | 0.03% | 647 |
|
|
2020
Q4 | $75.2M | Buy |
543,274
+51,080
| +10% | +$6.06M | 0.03% | 549 |
|
|
2020
Q3 | $40.5M | Buy |
492,194
+117,402
| +31% | +$9.73M | 0.02% | 772 |
|
|
2020
Q2 | $29.3M | Buy |
374,792
+31,693
| +9% | +$2.1M | 0.01% | 913 |
|
|
2020
Q1 | $15.2M | Buy |
343,099
+7,520
| +2% | +$390K | 0.01% | 1187 |
|
|
2019
Q4 | $14.3M | Buy |
335,579
+5,886
| +2% | +$243K | 0.01% | 1439 |
|
|
2019
Q3 | $14.1M | Buy |
329,693
+11,275
| +4% | +$613K | 0.01% | 1375 |
|
|
2019
Q2 | $20.2M | Buy |
318,418
+17,415
| +6% | +$1.11M | 0.01% | 1127 |
|
|
2019
Q1 | $20.9M | Buy |
301,003
+39,392
| +15% | +$2.25M | 0.01% | 1075 |
|
|
2018
Q4 | $11.4M | Buy |
261,611
+3,334
| +1% | +$182K | 0.01% | 1368 |
|
|
2018
Q3 | $19.7M | Buy |
258,277
+13,557
| +6% | +$1.1M | 0.01% | 1150 |
|
|
2018
Q2 | $18.8M | Buy |
244,720
+21,566
| +10% | +$1.39M | 0.01% | 1138 |
|
|
2018
Q1 | $11.4M | Buy |
223,154
+50,615
| +29% | +$2.55M | 0.01% | 1403 |
|
|
2017
Q4 | $8M | Sell |
172,539
-8,931
| -5% | -$438K | 0.01% | 1635 |
|
|
2017
Q3 | $9.67M | Sell |
181,470
-37,945
| -17% | -$2.25M | 0.01% | 1464 |
|
|
2017
Q2 | $13.6M | Buy |
219,415
+7,618
| +4% | +$459K | 0.01% | 1116 |
|
|
2017
Q1 | $14.4M | Buy |
211,797
+12,976
| +7% | +$989K | 0.01% | 1058 |
|
|
2016
Q4 | $14M | Buy |
198,821
+14,409
| +8% | +$1.02M | 0.02% | 1007 |
|
|
2016
Q3 | $13.1M | Buy |
184,412
+13,606
| +8% | +$868K | 0.02% | 968 |
|
|
2016
Q2 | $8.36M | Buy |
170,806
+2,071
| +1% | +$134K | 0.01% | 1204 |
|
|
2016
Q1 | $10.7M | Buy |
168,735
+14,947
| +10% | +$978K | 0.01% | 1004 |
|
|
2015
Q4 | $17.3M | Buy |
153,788
+11,497
| +8% | +$1.15M | 0.02% | 666 |
|
|
2015
Q3 | $13.7M | Buy |
142,291
+49,634
| +54% | +$5.68M | 0.02% | 765 |
|
|
2015
Q2 | $9.49M | Buy |
92,657
+39,729
| +75% | +$3.08M | 0.01% | 1077 |
|
|
2015
Q1 | $3.29M | Buy |
52,928
+11,284
| +27% | +$627K | ﹤0.01% | 1772 |
|
|
2014
Q4 | $1.83M | Buy |
41,644
+2,376
| +6% | +$109K | ﹤0.01% | 2068 |
|
|
2014
Q3 | $2.22M | Buy |
39,268
+24,440
| +165% | +$1.23M | ﹤0.01% | 1907 |
|
|
2014
Q2 | $666K | Buy |
14,828
+9,804
| +195% | +$404K | ﹤0.01% | 2516 |
|
|
2014
Q1 | $246K | Buy |
+5,024
| New | +$259K | ﹤0.01% | 2884 |
|
Other funds holding RARE
RI
FCM
Charles Schwab's RARE Position: Q2 2026 in Review
Charles Schwab increased its Ultragenyx Pharmaceutical (RARE) stake by 36% in Q2 2026, buying an estimated $5.01M and bringing the position to 760,039 shares worth $25.4M. The position accounts for ﹤0.01% of the portfolio, ranked #1691.
Charles Schwab first reported a position in RARE in Q1 2014 and has held it in 50 quarters since. The position peaked at $75.2M in Q4 2020. 310 funds tracked by Wall St. Rank hold RARE as of Q2 2026.
- Charles Schwab held 760,039 shares of Ultragenyx Pharmaceutical worth $25.4M as of Q2 2026.
- Charles Schwab bought 201,553 Ultragenyx Pharmaceutical shares in Q2 2026, an estimated $5.01M.
- Ultragenyx Pharmaceutical made up ﹤0.01% of Charles Schwab's portfolio in Q2 2026, its #1691 holding.
- Charles Schwab first reported a position in Ultragenyx Pharmaceutical in Q1 2014 and has held it in 50 quarters since.
- Charles Schwab's Ultragenyx Pharmaceutical position peaked at $75.2M in Q4 2020.
- 310 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2026.
Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.